Will taking L-Tryptophan likely to cause schitzophrenia?

Hi guys,

Is there any danger of taking the L-Tryptophan?

I am not talking about the EMS cases.

My concern with taking the L-Tryptophan is what it is said on the Wikipedia.org

"Tryptophan has been implicated as a possible cause of schizophrenia in people who cannot metabolize it properly. When improperly metabolized, it creates a waste product in the brain that is toxic, causing hallucinations and delusions." (L-tryptophan, wikipedia.org)

Is it true that it can cause schizophrenia?

I do not want to take 5-htp.

Is taking the L-Tryptophan safe?

thanks

Answers:
I would think it would be safe for most people. It is naturally occuring in turkey. I have taken it before and it was fine, I didn't have any negative mental problems because of it.

hv a word wid u're doc......vl help you decide better mate!
Always ask your docctor these type of questions, Wikiedia may have answers but it jis better to ask the doctor that prescribed them. Better to get any of these meds better from a psychiatris than a doctor , He / She specializes in the treatment of Mental Health , than internal med or fammily practice. Some donrt even know the interactions. Better ask. but It wont cause no it wont c

U. S. Food and Drug Administration
Center for Food Safety and Applied Nutrition
Office of Nutritional Products, Labeling, and Dietary Supplements
February 2001


Information Paper on L-tryptophan and 5-hydroxy-L-tryptophan
Background | Current policy | Reporting problems
------------------------------.

Background on L-tryptophan and 5-hydroxy L-tryptophan and the eosinophilia myalgia syndrome
FDA took action to limit the availability of dietary supplements containing the amino acid that is the biological precursor of L-5-hydroxytryptophan, that is, L-tryptophan, because of the association between dietary supplements containing L-tryptophan and the 1989 epidemic outbreak of eosinophilia-myalgia syndrome (EMS) in the United States. In the summer and fall of 1989, an epidemic outbreak of eosinophilia-myalgia syndrome (EMS) occurred in the United States. This illness is associated with the use of dietary supplements containing L-tryptophan. In all, more than 1500 cases of EMS, including at least 37 deaths, have been reported to the national Centers for Disease Control and Prevention (CDC), although the true incidence of the disorder is thought to be much higher. Some individuals suffering from L-tryptophan-related EMS have recovered, while other individuals' illnesses have persisted or worsened over time.

In certain epidemiological studies, more than 95 percent of the cases of EMS were traced to L-tryptophan supplied by Showa Denko K.K. of Japan. However, many people who consumed Showa Denko L-tryptophan did not develop EMS and cases of EMS and a related disease, eosinophilic fascitis, have occurred prior to and after the 1989 epidemic. EMS and related disorders are also reported to be associated with exposure to L-5-hydroxytryptophan, which is not made in the same manner as L-tryptophan (e.g., via fermentation processes). Based on these observations, FDA concluded that other brands of L-tryptophan, or L-tryptophan itself, regardless of the levels or presence of impurities, could not be eliminated as causal or contributing to the development of EMS. The serious nature of this disease necessitates that caution be exercised.

Numerous trace level impurities have been identified in the L-tryptophan implicated in many of the EMS cases. Based on the epidemiologic data, several of these impurities, including 1,1'-ethylidenebis[L-tryptopha. (EBT), have been associated with EMS. However, the role, if any, of these impurities in EMS is unclear. Animal studies in the Lewis rat showed that EBT caused some, but not all, of the pathologic effects associated with EMS. In addition, these studies showed that significant myofascial thickening and pancreatic fibrosis occurred in rats treated with the control L-tryptophan that did not contain EBT. These data, as well as data from a number of experiments employing different strains or species of animals indicate that L-tryptophan, when ingested by susceptible individuals either alone or in combination with some other component in the product, results in the pathological features in EMS. These findings raise serious questions regarding the safety of high dose levels of "uncontaminated" L-tryptophan. EBT and the other impurities epidemiologically associated with the EMS epidemic cases may only be markers for a yet unidentified substance(s) which trigger(s) EMS in a susceptible host. Other environmental factors could also act as "triggers."

Taken together, these findings support previous suggestions that the L-tryptophan-associated EMS was caused by several factors and is not necessarily related to a impurity in a single source of L-tryptophan. Based on the scientific evidence that is available at the present time, we cannot determine with certainty that the occurrence of EMS in susceptible persons consuming L-tryptophan supplements derives from the content of L-tryptophan, an impurity contained in the L-tryptophan, or a combination of the two in association with other, as yet unknown, external factors. Furthermore, results from published studies suggest that the risk of developing EMS may be linked in part to different patterns of xenobiotic metabolism and immune response genes in patients with EMS. Consequently, FDA cannot determine that oral dosage forms of L-tryptophan and related compounds such as L-5-hydroxytryptophan can be safely used as dietary supplements.


Current policy on the marketing of dietary supplements containing L-tryptophan and related compounds

Although FDA continues to enunciate its concern about the safety of dietary supplements containing L-tryptophan and related compounds such as L-5-hydroxytryptophan, this does not mean that FDA prohibits the marketing of dietary supplements that contain L-tryptophan. Under the Food, Drug and Cosmetic Act (the Act), as amended by the Dietary Supplement Health and Education Act of 1994 (DSHEA), the manufacturer is responsible for ensuring that its products are safe. A firm is not required to obtain premarket review or approval from the FDA of its products before marketing them as dietary supplements. Moreover, a firm is not required to submit scientific evidence to FDA of the safety of its products or ingredients. While we are unaware of conclusive scientific data that would establish that a dietary supplement L-tryptophan would be safe, if a firm has information that it believes establishes that a product containing L-tryptophan is safe within the meaning of the Act, it could market such a product as a dietary supplement. The burden and responsibility for assuring that such a product is not adulterated under the Act is with the firm and not FDA.

At the present time, an import alert remains in force which limits the importation of L-tryptophan into the United States, except if it is intended for an exempted use. FDA has provided for the use of manufactured L-tryptophan for special dietary purposes. Manufactured L-tryptophan is a lawful and essential component of foods, such as infant formulas, enteral products and approved parenteral drug products, in compliance with Title 21 of the Code of Federal Regulations (21CFR) Part 172.320. L-tryptophan may also be added as a nutrient to special dietary foods, which are intended for use under medical supervision. FDA continues to permit the use of L-tryptophan in accordance with the provisions of 21 CFR 172.320(f) in these types of foods, that are intended for use sole under medical supervision to meet nutritional requirements in specific medical conditions, since removal of L-tryptophan from this permitted use could result in a life-threatening situation for infants or other patients dependent on these products for sustenance.


Reporting of problems associated with the use of L-tryptophan or 5-hydoxy L-tryptophan containing dietary supplements:

Adverse Event Reporting
Reporting Unlawful Sales of Medical Products on the Internet
MedWatch




------------------------------.


This document was issued in February 2001.
For more recent information on Dietary Supplements
See http://www.cfsan.fda.gov/~dms/supplmnt.html




------------------------------.
Dietary Supplements
------------------------------.
Foods Home | FDA Home | Search/Subject Index | Disclaimers & Privacy Policy
Hypertext updated by las/kwg 2001-APR-04
ause.schizophrenia

U. S. Food and Drug Administration
Center for Food Safety and Applied Nutrition
Office of Nutritional Products, Labeling, and Dietary Supplements
February 2001


Information Paper on L-tryptophan and 5-hydroxy-L-tryptophan
Background | Current policy | Reporting problems
------------------------------.

Background on L-tryptophan and 5-hydroxy L-tryptophan and the eosinophilia myalgia syndrome
FDA took action to limit the availability of dietary supplements containing the amino acid that is the biological precursor of L-5-hydroxytryptophan, that is, L-tryptophan, because of the association between dietary supplements containing L-tryptophan and the 1989 epidemic outbreak of eosinophilia-myalgia syndrome (EMS) in the United States. In the summer and fall of 1989, an epidemic outbreak of eosinophilia-myalgia syndrome (EMS) occurred in the United States. This illness is associated with the use of dietary supplements containing L-tryptophan. In all, more than 1500 cases of EMS, including at least 37 deaths, have been reported to the national Centers for Disease Control and Prevention (CDC), although the true incidence of the disorder is thought to be much higher. Some individuals suffering from L-tryptophan-related EMS have recovered, while other individuals' illnesses have persisted or worsened over time.

In certain epidemiological studies, more than 95 percent of the cases of EMS were traced to L-tryptophan supplied by Showa Denko K.K. of Japan. However, many people who consumed Showa Denko L-tryptophan did not develop EMS and cases of EMS and a related disease, eosinophilic fascitis, have occurred prior to and after the 1989 epidemic. EMS and related disorders are also reported to be associated with exposure to L-5-hydroxytryptophan, which is not made in the same manner as L-tryptophan (e.g., via fermentation processes). Based on these observations, FDA concluded that other brands of L-tryptophan, or L-tryptophan itself, regardless of the levels or presence of impurities, could not be eliminated as causal or contributing to the development of EMS. The serious nature of this disease necessitates that caution be exercised.

Numerous trace level impurities have been identified in the L-tryptophan implicated in many of the EMS cases. Based on the epidemiologic data, several of these impurities, including 1,1'-ethylidenebis[L-tryptopha. (EBT), have been associated with EMS. However, the role, if any, of these impurities in EMS is unclear. Animal studies in the Lewis rat showed that EBT caused some, but not all, of the pathologic effects associated with EMS. In addition, these studies showed that significant myofascial thickening and pancreatic fibrosis occurred in rats treated with the control L-tryptophan that did not contain EBT. These data, as well as data from a number of experiments employing different strains or species of animals indicate that L-tryptophan, when ingested by susceptible individuals either alone or in combination with some other component in the product, results in the pathological features in EMS. These findings raise serious questions regarding the safety of high dose levels of "uncontaminated" L-tryptophan. EBT and the other impurities epidemiologically associated with the EMS epidemic cases may only be markers for a yet unidentified substance(s) which trigger(s) EMS in a susceptible host. Other environmental factors could also act as "triggers."

Taken together, these findings support previous suggestions that the L-tryptophan-associated EMS was caused by several factors and is not necessarily related to a impurity in a single source of L-tryptophan. Based on the scientific evidence that is available at the present time, we cannot determine with certainty that the occurrence of EMS in susceptible persons consuming L-tryptophan supplements derives from the content of L-tryptophan, an impurity contained in the L-tryptophan, or a combination of the two in association with other, as yet unknown, external factors. Furthermore, results from published studies suggest that the risk of developing EMS may be linked in part to different patterns of xenobiotic metabolism and immune response genes in patients with EMS. Consequently, FDA cannot determine that oral dosage forms of L-tryptophan and related compounds such as L-5-hydroxytryptophan can be safely used as dietary supplements.


Current policy on the marketing of dietary supplements containing L-tryptophan and related compounds

Although FDA continues to enunciate its concern about the safety of dietary supplements containing L-tryptophan and related compounds such as L-5-hydroxytryptophan, this does not mean that FDA prohibits the marketing of dietary supplements that contain L-tryptophan. Under the Food, Drug and Cosmetic Act (the Act), as amended by the Dietary Supplement Health and Education Act of 1994 (DSHEA), the manufacturer is responsible for ensuring that its products are safe. A firm is not required to obtain premarket review or approval from the FDA of its products before marketing them as dietary supplements. Moreover, a firm is not required to submit scientific evidence to FDA of the safety of its products or ingredients. While we are unaware of conclusive scientific data that would establish that a dietary supplement L-tryptophan would be safe, if a firm has information that it believes establishes that a product containing L-tryptophan is safe within the meaning of the Act, it could market such a product as a dietary supplement. The burden and responsibility for assuring that such a product is not adulterated under the Act is with the firm and not FDA.

At the present time, an import alert remains in force which limits the importation of L-tryptophan into the United States, except if it is intended for an exempted use. FDA has provided for the use of manufactured L-tryptophan for special dietary purposes. Manufactured L-tryptophan is a lawful and essential component of foods, such as infant formulas, enteral products and approved parenteral drug products, in compliance with Title 21 of the Code of Federal Regulations (21CFR) Part 172.320. L-tryptophan may also be added as a nutrient to special dietary foods, which are intended for use under medical supervision. FDA continues to permit the use of L-tryptophan in accordance with the provisions of 21 CFR 172.320(f) in these types of foods, that are intended for use sole under medical supervision to meet nutritional requirements in specific medical conditions, since removal of L-tryptophan from this permitted use could result in a life-threatening situation for infants or other patients dependent on these products for sustenance.


Reporting of problems associated with the use of L-tryptophan or 5-hydoxy L-tryptophan containing dietary supplements:

Adverse Event Reporting
Reporting Unlawful Sales of Medical Products on the Internet
MedWatch




------------------------------.


This document was issued in February 2001.
For more recent information on Dietary Supplements
See http://www.cfsan.fda.gov/~dms/supplmnt.html




------------------------------.
Dietary Supplements
------------------------------.
Foods Home | FDA Home | Search/Subject Index | Disclaimers & Privacy Policy
Hypertext updated by las/kwg 2001-APR-04
Ask a doctor. Tell him/her your concerns and if you have had any frightening episodes. He/she might ask you for a blood test.

Good luck
mm i wouldnt know...
L-tryptophan can only affect you mildly. It cannot cause schizophrenia unless you were predisposed to the disease and recieved impossibly large amounts of the amino acid.

Why don't you want to take 50-HTP? It helped me a little in my depression. Not enough to be a final solution, but I did notice a lift as I used it in conjunction with heliotherapy (light therapy) to treat SAD(seasonal affective disorder)-like symptoms.

Rule of psychology - Correlation does not equal Causation.

If you want tryptophan, eat Thanksgiving dinner. Have you noticed everyone sleeping after dinner, after they start to watch the game? That's tryptophan from the turkey(supposedly). Along with overeating. And vacation. And higher stress levels with extended family around. Okay, so maybe tryptophan has nothing to do with the sleeping. We like to make connections sometimes.
Many people seem to be able to take it. I wouldn't though. I do not think it is that beneficial and why take the risks?
Safe as the milk it's in.
You answer was in your quote!
People who have schizophrenia cannot properly metaboilze the Trptophan instead of the natural processes their brain creates a toxic chemical responsable for the delusions.
If you have a normal brain you should be able to metabolize it without any ill effects.
I used to take L-tryptophan to help me relax and get to sleep. A few years back they took it off the counters at health food and herb shops due to new dangers as side effects. I don't think I'd take it again.It could be very dangerous depending on how your body metabolizes it.
it can cause symptoms of schizophrenia but the symptoms should clear once it is stopped. personally, i would avoid it.
Tryptan is quite safe and used in conjunction with an antidepressant has in some cases had good results. It is a naturally occurring enzyme which is the precursor to Serotonin, the neurotransmitter that controls mood and sleep. Obviously we do not get enough in our diet if there is a shortage of serotonin so we have to take it in higher concentrations in tablet form to produce the desired results. It can be taken alone and has mild antidepressant effects but better as an adjunct to another antidepressant (which should be tried alone first)
The page content post from users, we do not guarantee its accuracy. If you belong to the copyright which contains information, please contact us to remove it.
More Questions...